Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

Core Insights - Immunocore Holdings PLC reported a revenue of $93.88 million for the quarter ended March 2025, reflecting a year-over-year increase of 33.2% [1] - The earnings per share (EPS) for the quarter was $0.10, a significant improvement from -$0.49 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $87.06 million by 7.84%, while the EPS surpassed the consensus estimate of -$0.35 by 128.57% [1] Revenue Breakdown - Geographic revenue from the United States was $56.61 million, which fell short of the two-analyst average estimate of $65.33 million [4] - International revenue reached $4.47 million, exceeding the two-analyst average estimate of $2.67 million [4] - Revenue from Europe was $32.80 million, significantly higher than the average estimate of $18.53 million based on two analysts [4] - Overall product revenue netted $93.88 million, surpassing the average estimate of $85.61 million from four analysts [4] Stock Performance - Immunocore's shares have returned +14.4% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]